Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial

NCT02258659 is registered in ClinicalTrials.gov with University of Chicago as lead sponsor.

NCT NCT02258659
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02258659 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Exploratory Pilot Study of Nab-paclitaxel Based Induction Chemotherapy Followed by Response-Stratified Locoregional Therapy for Patients With Stage III and IV HPV-Related Oropharyngeal Cancer - the OPTIMA HPV Trial
Lead sponsor
University of Chicago
Phase
Phase 2
Overall status
Completed
Start date
September 22, 2014
Completion date
September 6, 2024
Enrollment
62 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

human papilloma virus infection, stage iii squamous cell carcinoma of the oropharynx, stage iva squamous cell carcinoma of the oropharynx, stage ivb squamous cell carcinoma of the oropharynx